Boehringer Ingelheim has announced the launch of INGELVAC CIRCOFLEX® AD, the first U.S. swine vaccine to combine protection against both PCV2a and PCV2d genotypes in a single dose.
The new vaccine arrives as the industry adapts to the growing dominance of PCV2d, now the most prevalent genotype in the U.S. and globally. Built on nearly two decades of success with the original INGELVAC CIRCOFLEX®, this updated version reflects Boehringer’s commitment to innovating swine health solutions amid changing disease dynamics.
Advanced Protection for Producers
According to Boehringer, INGELVAC CIRCOFLEX® AD provides:
-
Broad protection against PCV2a and PCV2d, which account for over 90% of clinical cases
-
Fast onset of immunity within two weeks
-
At least six months of protection to support long-term herd health
“This next-generation vaccine offers broader, safer, longer-lasting immunity to help producers stay ahead of evolving PCV2 threats,” said Steve Boren, Vice President, U.S. Livestock at Boehringer Ingelheim.
Supporting Herd Health and Performance
Porcine circovirus type 2 (PCV2) is one of the most economically damaging viruses in swine production, causing porcine circovirus associated disease (PCVAD), which can result in weight loss, respiratory challenges, diarrhea, and increased susceptibility to co-infections.
By combining both key antigens into a single, 1-mL intramuscular dose, INGELVAC CIRCOFLEX® AD streamlines vaccination protocols while providing robust immune defense with Boehringer’s trusted IMPRANFLEX® adjuvant for improved safety and performance.
Available Now for U.S. Producers
INGELVAC CIRCOFLEX® AD is approved for use in healthy pigs as early as two weeks of age and is available in both 50-dose and 250-dose vials.
For more information, producers can visit Boehringer Ingelheim Animal Health
